Cardinal Health, Inc. vs Kia Corporation: Strategic Comparison

This in-depth comparison examines Cardinal Health, Inc. and Kia Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Cardinal Health, Inc. on its own, evaluating Kia Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Cardinal Health, Inc. and Kia Corporation is widest.

On the headline numbers, Cardinal Health, Inc. reports annual revenue of $254.2B against ~$81B for Kia Corporation, while their respective market capitalizations stand at $56.0B and $32.4B. Cardinal Health, Inc. is headquartered in United States and Kia Corporation in South Korea, and those different home markets shape how each company competes.

Cardinal Health, Inc.: Cardinal Health, based in Ohio, is one of the three large US pharmaceutical distributors, along with McKesson and Cencora. It does not invent drugs or treat patients. It runs the regulated supply chain that moves medicines and medical devices from manufacturers to pharmacies and hospitals, so a prescription collected at a local pharmacy has often passed through its network.

Kia Corporation: Kia Corporation (KRX: 000270), headquartered at 12 Heolleung-ro, Seocho-gu, Seoul, is the second automaker in Hyundai Motor Group. It has been listed since July 1973. Hyundai Motor Company holds 35.17% of its shares, and Hyundai and its related parties hold 36.99% together. Foreign investors own 40.32% and Korea's National Pension Service owns 7.25% (end of 2025). Kia designs and markets its vehicles separately from Hyundai, but the two share engineering, platforms and suppliers. In 2025 it sold 3,135,873 vehicles, its best year so far. The best sellers were the Sportage, Seltos, Sorento and Carnival, along with a growing range of hybrid and EV models.

Cardinal Health, Inc. and Kia Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Cardinal Health, Inc. and Kia Corporation.

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

Kia Corporation business model: Kia makes money mainly by building and selling vehicles wholesale to its regional sales subsidiaries, importers and franchised dealers, which then sell to retail and fleet buyers. SUVs and RVs such as the Sportage, Sorento, Seltos, Carnival and Telluride make up most of the mix and earn more per unit than small sedans. Parts, accessories, service and connected-car subscriptions (Kia Connect) bring in further revenue from cars already on the road. Kia shares platforms, powertrains, the 800-volt E-GMP EV architecture and many suppliers with Hyundai Motor, which spreads engineering costs across both brands. Hyundai Mobis and Hyundai WIA are its biggest related-party suppliers: Kia's 2025 transactions with them were about $6.67 billion (KRW 9.4 trillion) and ~$2.63 billion (KRW 3.7 trillion). Hyundai Capital provides much of the retail and dealer financing. A newer line of business is purpose-built vehicles (PBVs), starting with the PV5 electric van, which are sold to businesses for delivery, ride-hailing and fleet use.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Cardinal Health, Inc. stack up against those of Kia Corporation.

Cardinal Health, Inc. competitive advantage: Cardinal Health's advantage is physical scale and regulatory standing. Moving regulated, temperature-sensitive drugs and biologics across the country overnight takes a network of specialized distribution centers and security procedures that cost billions of dollars and take decades to build. The barrier to entry is high, so drug distribution is concentrated among a few large companies.

Kia Corporation competitive advantage: Kia's main advantages are its scale inside Hyundai Motor Group and the way it can switch powertrains easily. Sharing platforms, the E-GMP 800V EV architecture, batteries, chips and logistics (Hyundai Glovis) with Hyundai lowers development and purchasing costs. Factories in Korea, the US (Georgia), Mexico, Slovakia and India let Kia shift production between combustion, hybrid and electric models. In the US, the 10-year/100,000-mile powertrain warranty and award-winning models (EV6, EV9, Telluride) have built buyer trust that its 1990s cars never had.

Future prospects matter as much as current results. The growth strategies below explain how Cardinal Health, Inc. and Kia Corporation each plan to expand from here.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

Kia Corporation growth strategy: Kia's current strategy, set out at the 2026 CEO Investor Day, uses several powertrains instead of only EVs. It plans to grow EVs (EV3, EV4, EV5, EV6, EV9 and later models) and hybrids together, add a PBV line of modular electric vans starting with the PV5, and build up software-defined vehicles, autonomous driving and robotics as longer-term businesses. By 2030 it is targeting 1.02 million sales in the US and 746,000 in Europe, along with growth in India and other emerging markets.

A closer look at the financial trajectory of Cardinal Health, Inc. and Kia Corporation rounds out the comparison.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%.

Kia Corporation: Kia's revenue has risen every year since 2020: from ~$49.6 billion (KRW 69.9 trillion) in 2021 to ~$76.3 billion (KRW 107.4 trillion) in 2024 and a record ~$81 billion (KRW 114.1 trillion) in 2025 (+6.2%). Profit has not kept up. Operating profit fell 28.3% in 2025 to ~$6.45 billion (KRW 9.08 trillion), and the margin dropped from 11.8% to 8.0% as US tariffs and incentives ate into earnings. Net profit was about $5.36 billion (KRW 7.55 trillion). The squeeze continued into 2026. Q1 revenue was a record ~$20.9 billion (KRW 29.50 trillion) (+5.3%), but operating profit fell 26.7% to ~$1.57 billion (KRW 2.21 trillion). Q2 revenue reached ~$23.5 billion (KRW 33.04 trillion) (+12.6%) while operating profit fell 4.9% to ~$1.87 billion (KRW 2.63 trillion). The shares dropped about 13% on the day of the Q2 results. Shareholder returns are still high: the 2025 dividend was KRW 6,800 per share, a 35% consolidated payout ratio, and Kia has been cancelling treasury shares, cutting issued shares from 405.4 million in 2022 to 390.4 million at the end of 2025.